



8 May 2014

COMPANY ANNOUNCEMENT

Phosphagenics Limited

2013 Annual Report & 2014 Annual General Meeting

The 2013 Annual Report for the financial year ended 31 December 2013, together with documentation for the 2014 Annual General Meeting ("AGM"), were released to the market on 17 April 2014.

The 2014 AGM is to be held on Friday 23 May 2014 commencing at 3.00 p.m. on Level 2, Bourke Room at the RACV City Club:

501 Bourke Street
Melbourne Vic

The AGM documentation, together with a copy of the Annual Report for those members who have opted to receive a printed copy of the Report, has been dispatched to members. These documents can also be viewed on the Company's website as noted below.

In addition, electronic notification of the availability of these documents has been broadcast via the Share Registrar.

About Phosphagenics

Phosphagenics Limited is commercialising drug delivery applications based on its novel transdermal (drugs administered via skin) TPM[®] – Targeted Penetration Matrix technology. TPM[®] is a patient friendly and cost effective system used to deliver proven pharmaceutical and nutraceutical products.

The lead product advancing through clinical trials is an oxycodone and oxymorphone matrix system for the relief of chronic pain.

Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

www.phosphagenics.com
www.elixia.com.au

Phosphagenics Limited

ACN 056 482 403 ABN 32 056 482 403

11 Duerdin Street, Clayton Vic 3168

Telephone: 61 3 9565 1119 Facsimile: 61 3 9565 1151

: www.phosphagenics.com Email: info@phosphagenics.com